Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens

Abera Abdeta1*, Adane Bitew2, Surafel Fentaw1, Estifanos Tsige1, Dawit Assefa1, Tadesse Lejisa3, Yordanos Kefyalew4, Eyasu Tigabu5, Martin Evans6

1 National Clinical Bacteriology and Mycology Reference Laboratory, Ethiopian Public Health Institute, Addis Ababa, Ethiopia, 2 Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia, 3 National Clinical Chemistry Reference Laboratory, Ethiopian Public Health Institute, Addis Ababa, Ethiopia, 4 Department of Applied Biology, School of Applied Natural Science, Adama Science and Technology University, Adama, Ethiopia, 5 Global One Health initiative, The Ohio State University, East African Regional Office, Addis Ababa, Ethiopia, 6 Laboratory Director and Microbiology Consultant, New York, New York, United States of America

* aberaabdeta4@gmail.com

Abstract

Background
Multidrug resistant, extremely drug-resistant, pan-drug resistant, carbapenem-resistant, and carbapenemase-producing gram-negative bacteria are becoming more common in health care settings and are posing a growing threat to public health.

Objective
The study was aimed to detect and phenotypically characterize carbapenem non-susceptible gram-negative bacilli at the Ethiopian Public Health Institute.

Materials and methods
A prospective cross-sectional study was conducted from June 30, 2019, to May 30, 2020, at the national reference laboratory of the Ethiopian Public Health Institute. Clinical samples were collected, inoculated, and incubated for each sample in accordance with standard protocol. Antimicrobial susceptibility testing was conducted using Kirby-Bauer disk diffusion method. Identification was done using the traditional biochemical method. Multidrug-resistant and extensively drug-resistant isolates were classified using a standardized definition established by the European Centre for Disease Prevention and Control and the United States Centers for Disease Prevention and Control. Gram-negative organisms with reduced susceptibility to carbapenem antibiotics were considered candidate carbapenemase producers and subjected to modified carbapenem inactivation and simplified carbapenem inactivation methods. Meropenem with EDTA was used to differentiate metallo-β-lactamase (MBL) from serine carbapenemase. Meropenem (MRP)/meropenem + phenylboronic acid (MBO) were used to differentiate Klebsiella pneumoniae carbapenemase (KPC) from other serine carbapenemase producing gram-negative organisms.
Results
A total of 1,337 clinical specimens were analyzed, of which 429 gram-negative bacterial isolates were recovered. Out of 429 isolates, 319, 74, and 36 were Enterobacterales, Acinetobacter species, and Pseudomonas aeruginosa respectively. In our study, the prevalence of multidrug-resistant, extensively drug-resistant, carbapenemase-producing, and carbapenem nonsusceptible gram-negative bacilli were 45.2%, 7.7%, 5.4%, and 15.4% respectively. Out of 429 isolates, 66 demonstrated reduced susceptibility to the antibiotics meropenem and imipenem. These isolates were tested for carbapenemase production of which 34.8% (23/66) were carbapenemase producers. Out of 23 carbapenemase positive gram-negative bacteria, ten (10) and thirteen (13) were metallo-beta-lactamase and serine carbapenemase respectively. Three of 13 serine carbapenemase positive organisms were Klebsiella pneumoniae carbapenemase.

Conclusion
This study revealed an alarming level of antimicrobial resistance (AMR), with a high prevalence of multidrug-resistant (MDR) and extremely drug-resistant, carbapenemase-producing gram-negative bacteria, particularly among intensive care unit patients at the health facility level. These findings point to a scenario in which clinical management of infected patients becomes increasingly difficult and necessitates the use of “last-resort” antimicrobials likely exacerbating the magnitude of the global AMR crisis. This mandates robust AMR monitoring and an infection prevention and control program.

Introduction
The discovery of the antimicrobial agent is a fundamental milestone in the history of medicine and has saved millions of lives [1]. Antimicrobials were first used to treat infections in the 1940s [2]. Shortly after the discovery of antimicrobials, antimicrobial resistance emerged and with the recent increase in AMR, poses a serious threat to global public health [2].

The extensive use of antimicrobials for treating humans and animal infections along with globalization and international travel has led to the rapid spread of resistant strains [3]. The increasing incidence of healthcare-associated infections due to multidrug-resistant (MDR), extremely drug-resistant (XDR), and carbapenemase-producing gram-negative bacilli (GNB) has been widely reported [4–7].

The emergence and spread of multidrug-resistant gram-negative organisms (MDRO) pose serious threats to medical services and patient outcomes. Infections caused by carbapenemase-producing and carbapenem resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa result in increased patient morbidity and mortality. This can result in significant additional health-care costs for patient management as well as outbreak control [8–11].

Carbapenem-resistant and carbapenemase producing organisms such as E. coli, K. pneumoniae, Acinetobacter species and P. aeruginosa have become one of the most important causes of nosocomial and community-acquired infections. They can cause urinary tract, respiratory tract, bloodstream, meningitis, malignant external otitis, intra-abdominal infection and wound infections. Some of the important virulence factors that are implicated in these isolates include capsular polysaccharides, lipopolysaccharides, fimbrial adhesins, siderophores, efflux
pumps, hemolytic factors, iron acquisition system survival and immune evasion during infection [8–16].

Multidrug resistance has increased globally and is a major public health threat. Recent investigations reported the emergence of multidrug-resistant bacterial pathogens from different origins including humans, poultry, cattle, and fish that increase the need for routine application of antimicrobial susceptibility testing (AST) to select the antibiotic of choice as well as screening of emerging MDR strains [17–24].

International subject matter experts came together through a joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the United States Centers for Disease Control and Prevention (CDC), to create a standardized international definition with which to describe acquired resistance profiles [25].

MDR is defined as acquired nonsusceptibility to at least one agent in three or more antimicrobial categories, XDR as nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e., bacterial isolates remain susceptible to only one or two categories), and PDR (Pandrug-resistant) as nonsusceptibility to all agents in all antimicrobial categories. To apply these definitions, bacterial isolates should be tested against all or nearly all of the antimicrobial agents within the antimicrobial categories and selective reporting and suppression of results should be avoided [25].

The common mechanism of developing resistance to carbapenem antibiotics is through carbapenemase enzyme production [26]. Carbapenemase is the most versatile family of β-lactamases and recognizes almost all hydrolysable β-lactams, and most are resilient against inhibition by all available β-lactamase inhibitors [26]. Klebsiella pneumoniae carbapenemase (KPC) hydrolyzes penicillin, all cephalosporins, monobactams, carbapenems, and β-lactamase inhibitors. Metallo-β-lactamases usually exhibit resistance to penicillin, cephalosporins, carbapenems, and the clinically available β-lactamase inhibitors but are inhibited by monobactams [27].

There is a considerable knowledge gap regarding risk factors associated with the occurrence of MDR bacteremia [28]. Identifying risk factors for acquiring gram-negative bacteremia could potentially help patient care and management [28].

Despite the increasing global burden of multidrug resistance and carbapenemase-producing gram-negative bacilli, data on multidrug resistance and carbapenemase-producing gram-negative bacilli in Ethiopia is scarce. As a result, the objective of this study was to determine the prevalence of MDR, XDR, carbapenem non-susceptible and carbapenemase-producing gram-negative bacilli from various clinical specimens and to phenotypically characterize carbapenem non-susceptible isolates.

**Materials and methods**

**Study design, site, and period**

A prospective cross-sectional study was conducted from June 30, 2019, to May 30, 2020, at the National Clinical Bacteriology and Mycology Reference Laboratory on clinical samples collected the NRL and referred from different healthcare settings in Addis Ababa.

**Sample collection and processing**

Microbiological specimens from body fluids, ear swabs, sputum, urine, pus, cerebrospinal fluid, blood, and tracheal aspirates were processed following standard procedures [29]. Appropriate transport media were used in case of sample transportation delays. A total of 1,337 clinical specimens were collected during the study period. Specimens collected from each patient were inoculated onto culture media and incubated at appropriate temperatures and periods.
according to standard protocols related to each sample [29]. Identification was done using the conventional biochemical method [29]. Gram staining, colony characterization, and biochemical tests were conducted as part of the identification process. AST was done by the Kirby Baur disk diffusion method as per CLSI M100 2020. All frequently isolated Enterobacterales, Acinetobacter species, and P. aeruginosa recovered from the various clinical specimens during the study period were included. Necessary variables such as socio-demographics (age and sex), specimen type, referring health facilities, patient location, and previous antibiotic exposure from the test request form were entered onto pre-configured WHONET software version 2019.

**Bacterial isolation, identification and antimicrobial susceptibility testing**

**Bacterial isolation and identification.** The specimens were inoculated onto appropriate culture media, incubated at appropriate temperature and time following standard procedure [29]. The growth was inspected to identify the bacteria. Initial identification of bacteria was done based on Gram reaction and colonial morphology. Gram-negative rods were identified by performing a series of traditional biochemical enzymatic and carbohydrate fermentative tests on triple sugar iron agar (Liofilchem, Roseto degli Abruzzi, Italy), oxidase strips (Liofilchem, Roseto degli Abruzzi, Italy), Simon’s citrate agar (Liofilchem, Roseto degli Abruzzi, Italy), and lysine iron agar (Liofilchem, Roseto degli Abruzzi, Italy). Indole production and motility were obtained using sulfide-indole-motility (SIM) medium (Liofilchem, Roseto degli Abruzzi, Italy). Urease production was obtained using a urea agar base supplemented with 40% urea solution (Oxoid Ltd., Basingstoke, Hampshire, England).

**Antimicrobial susceptibility testing.** The Kirby Bauer disk diffusion method was used with Muller Hinton agar (Oxoid Ltd. Basingstoke, Hampshire, England) to determine antimicrobial susceptibility patterns of the isolates and CLSI M100 2020 was used to interpret the results [30].

The following antimicrobial discs were used: ampicillin (10μl), amoxicillin/clavulanic acid (20/10μl), piperacillin/tazobactam (100/10μl), cefazolin (30μl), cefuroxime (30μl), ceftazidime (30μl) obtained from Hardy Diagnostics, Santa Maria, CA, USA. Ceftriaxone (30μl), cefotaxime (30μl), imipenem (10μl), meropenem (10μl), amikacin (30μl), gentamicin (10μl), and tobramycin(10μl) were obtained from OXOID LTD., Basingstoke, Hampshire, England. Nalidixic acid(30μl), ciprofloxacin(5μl), trimethoprim/sulfamethoxazole (1.25/23.75μl), nitrofurantoin(300μl), and tetracycline(30μl) from Liofilchem, Roseto degli Abruzzi, Italy.

**Detection of carbapenemase**

The Clinical and Laboratory Standards Institute CLSI (2010) introduced the modified Hodge test for carbapenemase detection, but this method can only be used for the accurate detection of KPC-type carbapenemase in Enterobacterales [31]. CLSI (2012) recommended the Carba NP test method for the detection of carbapenemase in gram-negative bacilli; however, the preparation of the reagents required for this test is complicated and the solutions cannot be stored for extended periods, limiting its clinical application [32].

In 2015, the carbapenem inactivation method (CIM) which is easy to operate and highly sensitive for the detection of carbapenemase was introduced [33]. In 2017, based on the CIM method, CLSI recommended the modified carbapenem inactivation method (mCIM). However, it is a relatively complex method and can only be used to detect carbapenemase in Enterobacterales and P. aeruginosa [34]. In 2018, based on the mCIM, a simplified carbapenem inactivation method (sCIM) was designed for accurate detection of carbapenemase in gram-negative bacilli [35].
**Modified carbapenem inactivation method.** In the mCIM, a 1 mL loopful of *Enterobacteriales* or a 10 mL loopful of *P. aeruginosa* from blood agar (Oxoid Ltd., Basingstoke, Hampshire, England) plates was emulsified in 2 mL trypticase soy broth (TSB) (Oxoid, Ltd., Basingstoke, Hampshire, England). A meropenem (10μl) disk (Oxoid Ltd., Basingstoke, Hampshire, England) was then immersed in the suspension and incubated for a minimum of 4 h at 35˚C. A 0.5 McFarland suspension of *E. coli* ATCC 25922 was prepared in saline using the direct colony suspension method. A Mueller Hinton agar (MHA) (Oxoid Ltd., Basingstoke, Hampshire, England) plate was inoculated with *E. coli* ATCC 25922 using the routine disk diffusion procedure. The meropenem disk was removed from the TSB and placed on a MHA plate previously inoculated with the *E. coli* ATCC 25922 indicator strain. Plates were incubated at 35˚C in ambient air for 18–24 h. An inhibition zone diameter of 6–15 mm or colonies within a 16–18 mm zone was considered to be a positive result, and a zone of inhibition of ≥19 mm was considered to be a negative result [30].

**Simplified carbapenem inactivation method.** The sCIM is based on the mCIM with an improved procedure. Instead of incubating the antimicrobial disk in the organism culture media for 4 hours as in the mCIM, the organism to be tested was smeared directly onto an antimicrobial disk in the sCIM. To perform the sCIM for *Acinetobacter* species, a 0.5 McFarland standard suspension (using direct colony suspension method) of *E. coli* ATCC 25922 was diluted 1:10 in saline and inoculated onto the MHA plate, following the routine disk diffusion procedure. Plates were allowed to dry for 3–10 min [35]. Subsequently, 1–3 colonies of the test organisms grown overnight on blood agar were smeared onto one side of an imipenem disk (10μg); immediately afterward, the side of the disk having bacteria was placed on the MHA plate previously inoculated with *E. coli* ATCC 25922. The imipenem disk placed on an MHA plate was used as the control [35]. All plates were incubated at 35˚C for 16–18 hours in ambient air. Bacterial strains that produced carbapenemase hydrolyze imipenem; hence the susceptible indicator strain grows unchecked. If the zone of inhibition around the disk gave a diameter of 6–20 mm, or the satellite growth of colonies of *E. coli* ATCC 25922 around the disk a zone diameter of ≤22 mm, the result was considered carbapenemase positive; a zone of inhibition ≥26 mm was considered to be a negative result; a zone of inhibition of 23–25 mm was considered to be a carbapenemase indeterminate result [35].

**Differentiation of metallo-β-lactamase from serine carbapenemases.** The modified carbapenem inactivation method positive *Enterobacteriales* (formerly *Enterobacteriaceae*) and *P. aeruginosa*, and the Simplified Carbapenem Inactivation Method positive *Acinetobacter* species detected were further screened for Class B metallo-carbapenemase (MBLs) which are characterized by inhibition with metal chelators like EDTA. Meropenem disks containing EDTA (Liofilchem, Roseto degli Abruzzi, Italy) were used to differentiate metallo-β-lactamase and serine carbapenemase. A ≥5-mm increase in zone diameter for eCIM vs. zone diameter for mCIM was considered MBL positive. A ≤4mm increase in zone diameter for the eCIM vs zone diameter of mCIM was considered MBL negative. Carbapenemase positive, metallo carbapenemase negative, gram-negative bacilli were considered serine carbapenemase producers [30].

Quality control recommendations: *K. pneumoniae* ATCC® BAA-1705™ *E. coli* ATCC® 25922™ were used as positive and negative controls respectively for meropenem with EDTA [30].

**Differentiation of Klebsiella pneumoniae carbapenemase (KPC) from other serine carbapenemases.** Serine carbapenemase producers were further screened for *Klebsiella pneumoniae* carbapenemase (KPC). Minimum inhibitory concentration (MIC) ug/mL KPC strips consisting of meropenem (MRP)/meropenem + phenylboronic acid (MBO) (Liofilchem,
Roseto degli Abruzzi, Italy) were used to detect *Klebsiella pneumoniae* carbapenemase (KPC) producing gram-negative isolates [36].

Well isolated colonies from an overnight blood agar plate were suspended in saline to achieve a 0.5 McFarland standard turbidity (1.0 McFarland if mucoid) to obtain a confluent lawn of growth after incubation. The strip was applied to the agar surface with the scale facing upwards and the code of the strip to the outside of the plate. The agar plates were incubated in an inverted position at 35 ± 2°C for 16–20 hours in an ambient atmosphere. The incubation time was extended to 48 hours to capture any slow-growing gram-negative non-fermenters [36].

**Result interpretation.** The ratio of MRP/MBO of ≥8 or ≥3 log2 dilutions was interpreted as a KPC producer. The phantom zone or deformation of the ellipse was interpreted as positive for KPC regardless of the MRP/MBO ratio [36].

**Quality control recommendations.** *K. pneumoniae ATCC® BAA-1705* (intrinsic KPC production) and *E. coli ATCC® 25922* and were used as positive and negative controls respectively to check the reactivity of KPC strips [36].

**Reagent quality assurance**
The quality of culture media, antimicrobial disks, and gradient strips were checked as per CLSI and EUCAST guidelines, laboratory SOPs, and the manufacturer’s instructions as applicable.

**Data analysis and interpretation**
The WHONET 2019 version was used to enter, clean, and analyze the data. The risk factors for MDR gram negative bacilli acquisition were examined by exporting WHONET data to SPSS statistics version 23. Tables and figures were used to present the results. Chi-square and univariate analysis were used to determine the association between multidrug-resistant gram-negative bacilli and different risk factors. P-values less than 0.05 were considered statistically significant.

**Ethical considerations**
The study was conducted after ethical clearance was obtained from the Department Research and Ethical Review Committee of the Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University. Official permission from the Ethiopian Public Health Institute was obtained. All results were kept confidential; the patient’s name and other personal identifiers were encrypted and the sample identifier automatically generated by the laboratory information system (LIS-Polytech) was used.

**Results**
During the study period, 1,337 specimens were analyzed providing 429 gram-negative isolates. Of these 293 were Enterobacterales, 74 were *Acinetobacter* species, and 36 were *P. aeruginosa*. The number of samples based on specimen types were as follows: blood (364), cerebrospinal fluid (46), ear swabs (28), other body fluids (30), pus (366), sputum (10), stool (18), tracheal aspirate (6), and urine (469). Of all GNB isolates, 233 and 196 isolates were recovered from specimens collected from male and female patients respectively.

Most of the isolates came from specimens referred from Aabet Hospital (187), Ras Desta Hospital (94), and Saint Peter’s Specialized Hospital (44). The distribution of GNB among health facilities is summarized in Fig 1.
The highest number of MDR, XDR, and carbapenemase-producing isolates were recovered from specimens referred from Aabet Hospital, Ras Desta Hospital, and Saint Peter’s Specialized Hospital. One hundred eighty-seven (187) GNB were recovered from Aabet Hospital specimens of which 130 (69.5%), 15 (8%), and 11 (5.9%) were MDR, XDR, and carbapenemase producers respectively. Ninety-four (94) GNB were recovered from Ras Desta Hospital specimens of which 40 (42.5%), 10 (10.6%), and 7 (7.4%) were MDR, XDR, and carbapenemase producers, respectively. The distribution of MDR, XDR, and carbapenemase-producing isolates among health facilities is summarized in Fig 2.

The prevalence of XDR gram-negative bacilli

Out of 429 GNB clinical isolates analyzed [33, 7.7%], were XDR; out of 33 XDR gram-negative isolates, Acinetobacter species were the predominant isolates 32.4% [24/74]. The remaining 9 XDR isolates were as follows; K. pneumoniae 2.7% [3/109], Proteus mirabilis 23.5% [4/17], E. cloacae 9% [1/11], and P. aeruginosa 2.7% [1/36] as summarized in Table 1. Of 33 XDR isolates [N = 21 or 63.64%] were isolated from intensive care units. The highest number of XDR gram-negative bacilli were isolated from urine samples [N = 16 or 48.48%]. The distribution of XDR isolates among specimen types, health facility wards and specimen sources is summarized in Table 1.

The prevalence of multi-drug resistance and carbapenemase-producing GNB

Of 429 isolates, 194 were MDR GNB isolates. The most frequently isolated MDR organism was K. pneumoniae [N = 80 or 73.4%] followed by Acinetobacter species [N = 52 or 70.3%], and E. coli [N = 36 or 23.6%]. The MDR GNB are summarized in Table 2.
Of 429 isolates, 15.4% (66/429) isolates were non-susceptible to either meropenem or imipenem. Carbapenem non-susceptible isolates were considered candidates for carbapenemase screening. Of 66 isolates screened for carbapenemase, 34.8% (23/66) were carbapenemase enzyme producers (Table 2). Ten of twenty-three (10/23) carbapenemase-positive organisms were metallo-B-lactamase (MBL) producers. Thirteen of twenty-three (13/23) isolates were serine carbapenemase producers. Three of thirteen (3/13) serine carbapenemase-positive organisms were Klebsiella pneumoniae carbapenemase (KPC) producers. Of 10 metallo-B-lactamase positive isolates, 5 (50%) were K. pneumoniae, and the remaining testing results are summarized in Table 2. The 3 KPC isolates were E. coli, K. pneumoniae, and P. aeruginosa (Table 2).

Table 1. Distribution of extremely drug-resistant gram-negative bacilli.

| Organism             | N  | %     | Ward          | N  | %     | Specimen type | N  | %     |
|----------------------|----|-------|---------------|----|-------|---------------|----|-------|
| Acinetobacter species | 24 | 72.73 | Intensive care unit | 21 | 63.64 | Urine         | 16 | 48.48 |
| K. pneumoniae        | 3  | 9.09  | Burn unit     | 2  | 6.06  | Blood         | 7  | 21.21 |
| P. mirabilis         | 4  | 12.12 | Orthopedics   | 3  | 9.09  | Sputum        | 1  | 3.03  |
| E. cloacae           | 1  | 3.03  | Unknown       | 6  | 18.18 | CSF           | 1  | 3.03  |
| P. aeruginosa        | 1  | 3.03  | Emergency     | 1  | 3.03  | Pus           | 8  | 24.24 |
| Total                | 33 | 100   | Total         | 33 | 100   | Total         | 33 | 100   |

XDR = Extremely drug-resistant; GNB = Gram-negative bacilli; N = Number; % = percentage
The prevalence of multi-drug resistant and extremely drug resistant, and carbapenemase-producing GNB. Of 194 MDR GNB isolates, 45% were isolated from patients admitted to the intensive care unit, 83.4% were isolated from patients previously exposed to different antimicrobial agents, 28% were isolated from patients under mechanical ventilation and/or urinary catheterization, and 34.7% were isolated from patients with hospital-acquired (HAI) pneumonia (Table 3).

Risk factors for acquiring multidrug resistant infections
Admission to an intensive care unit (OR:2.75, 95% CI: 1.92–3.95, P value: 0.001), mechanical ventilation as source of infection and/or urinary catheterization as source of infection (OR:3.6, 95% CI:2.3–5.6, P value:<0.001), HAI and/or HAI pneumonia as a source of infection (OR:2.94, 95% CI: 1.95–4.44, P value:<0.001), and recurrent urinary tract infection (OR:2.75, 95% CI:1.68–4.46, P value: <0.001), and sepsis originating from different focus (OR:15.83, 95% CI: 7.66–32.72, P value:0.001) were significantly associated with acquiring multidrug resistant gram-negative bacilli. (Table 3).

Univariate analysis of infections caused by MDR gram negative bacilli. Of 23 carbapenemase-positive organisms, 56.5% (13/23), 26.1% (6/23), 8.7% (2/23), 8.7% (2/23) were isolated from urine, pus, blood, and tracheal aspirate respectively (Table 4). Of 23 carbapenemase-positive organisms, 82.6% (19/23) and 17.4% (4/23) were isolated from the patients...
admitted to the intensive care unit and unknown ward respectively (Table 4). In this study the prevalence of carbapenem-nonsusceptible and carbapenemase-producing GNB is 15.4% (66/429) and 5.4% (23/429) respectively (Table 4).

| Specimen types | Carbanamemase Positive | Carbanamemase Negative | Total | Wards                       | Carbanamemase Positive | Carbanamemase Negative | Total |
|----------------|-------------------------|-------------------------|-------|----------------------------|-------------------------|-------------------------|-------|
| Blood          | 2                       | 7                       | 9     | Emergency                  | 0                       | 6                       | 6     |
| Pleural fluid  | 0                       | 1                       | 1     | ICU                        | 19                      | 22                      | 41    |
| Pus            | 6                       | 11                      | 17    | Inpatient                  | 0                       | 3                       | 3     |
| CSF            | 0                       | 2                       | 2     | outpatient                 | 0                       | 2                       | 2     |
| Tracheal aspirate | 2                  | 3                       | 5     | Unspecified                | 4                       | 10                      | 14    |
| Tissue         | 0                       | 1                       | 1     | Total                      | 23                      | 43                      | 66    |
| Urine          | 13                      | 18                      | 31    |                            |                         |                         |       |
| Total          | 23                      | 43                      | 66    |                            |                         |                         |       |

ICU-Intensive care unit, CSF-Cerebrospinal fluid

https://doi.org/10.1371/journal.pone.0256556.t004

Distribution of carbapenemase among wards and specimen sources

Phenotypic antimicrobial resistance patterns of Enterobacterales. Of 429 gram-negative isolates, 293 were the Enterobacterales family (E. coli, K. pneumoniae, K. oxytoca, K. ozae-nae) (Table 2). The highest resistance was observed against ampicillin by E. coli [89.3%] (Table 5). K. pneumoniae, K. oxytoca, and K. ozae-nae are intrinsically resistant to ampicillin hence not tested against them [30].

K. ozae-nae showed 100% resistance to first, second, and third generation cephalosporins as well as trimethoprim-sulfamethoxazole and Enterobacter cloacae demonstrated 100% resistance to ceftriazone. The overall resistance profile of Enterobacterales to extended-spectrum (3rd and 4th generation) cephalosporins ranges from ceftriazone [67.7%], cefotaxime [73.6%], ceftazidime [73.6%], and cefepime [66.5%]. E. coli showed high resistance to extended-spectrum cephalosporins, ceftriazone [63.8%], cefotaxime [68.6%], ceftazidime [65%] and cefepime [55.7%] (Table 5). K. pneumoniae showed high resistance to extended-spectrum cephalosporins; ceftriazone [88.7%], cefotaxime [82.8%], ceftazidime [81.1%], and cefepime [81.8%].

E. coli demonstrated high resistance to ciprofloxacin [62.9%] and trimethoprim-sulfamethoxazole [76.7%]; similarly, K. pneumoniae showed high resistance to ciprofloxacin [62.3%] and trimethoprim-sulfamethoxazole [82.7%] (Table 5). The overall prevalence of Enterobacterales resistance to gentamycin, tobramycin, and amikacin was 41.9%, 37.5%, and 6.1% respectively. The overall prevalence of meropenem and imipenem resistance among the Enterobacterales was 4.2% and 6.5% respectively.

Morganella morganii, P. mirabilis, and P. vulgaris were reorganized into the Morganellaceae family [30]. A total of 26 Morganellaceae isolates were identified during the study period (Table 2). M. morganii and P. vulgaris are intrinsically resistant to ampicillin, cefazolin, and cefuroxime and were not reported in Table 5. M. morganii, P. mirabilis, and P. vulgaris intrinsically resistant to antimicrobials (Table 5) and identified as Not Applicable/NA.

P. mirabilis showed 100% resistance to ampicillin, nalidixic acid, and trimethoprim-sulfamethoxazole; similarly, M. morganii demonstrated 100% resistance to nalidixic acid and trimethoprim-sulfamethoxazole. Morganellaceae showed high resistance percentage to ceftriazone [80.8%], cefotaxime [61%], ceftazidime [57.7%], and cefepime [63.6%].
percentages of meropenem and imipenem resistance were 14% and 14.3% respectively (Table 5). The antimicrobial susceptibility patterns of the Morganellaceae are summarized in Table 5. The percentage of Morganellaceae resistance among aminoglycosides ranges from 26.3% to 47.5% (Table 5).

**Phenotypic antimicrobial resistance patterns of Acinetobacter species**

Acinetobacter species show the highest level of resistance to cefotaxime [95.7%], ceftriaxone [94.7], ceftazidime [93%], tetracycline [92.9%], and cefepime [86.1%]. Acinetobacter species showed lowest resistance to amikacin [29.4%], meropenem [48.1%], imipenem [29.4%] (Table 5).

---

**Table 5. Antibiotic susceptibility pattern of gram-negative bacilli against different antimicrobial classes.**

|                      | E. coli | K. pneumoniae | K. oxytoca | K. ozonae | E. cloacae | P. mirabilis | P. vulgaris | M. morganii | Acinetobacter species | P. aeruginosa |
|----------------------|---------|---------------|------------|-----------|------------|--------------|------------|-------------|----------------------|--------------|
| **Ampicillin & β-lactam combinations** |          |               |            |           |            |              |            |             |                      |              |
| AMP %R              | 89.3    | NA            | NA*        | NA*       | 100        | NA*          | NA*        | NA*         | NA*                  | NA*          |
| AMC %R              | 33.8    | 64.4          | 33.3       | 87.5      | 38         | 0            | NA*        | NA*         | NA*                  | NA*          |
| TPZ %R              | 13.3    | 33.3          | 14.3       | 66.7      | 42.9       | 30           | 0          | 17          | 85.4                 | 12.5         |
| **1st and 2nd generation cephalosporins** |          |               |            |           |            |              |            |             |                      |              |
| CZ %R               | 60.4    | 85.7          | 57.1       | 100       | NA*        | 80           | NA*        | NA*         | NA*                  | NA*          |
| CXM %R              | 64.1    | 91.4          | 60         | 100       | 66.7       | 71           | NA*        | NA*         | NA*                  | NA*          |
| **Extended-spectrum cephalosporins** |          |               |            |           |            |              |            |             |                      |              |
| CRO %R              | 63.8    | 88.7          | 50         | 100       | 100        | 69           | 0          | 67          | 94.7                 | NA*          |
| CTX %R              | 68.6    | 82.8          | 60         | 100       | 25         | 68           | 0          | 67          | 95.7                 | NA*          |
| CAZ %R              | 65      | 81.1          | 33.3       | 100       | 71.4       | 83           | 0          | 0           | 93                   | 14.3         |
| FEP %R              | 55.7    | 81.8          | 40         | 85.7      | 75         | 89           | 0          | 0           | 86.1                 | 21.7         |
| **Carbapenems**     |          |               |            |           |            |              |            |             |                      |              |
| IPM %R              | 0       | 6.2           | 0          | 50        | 50         | 20           | 0          | 0           | 29.4                 | 0            |
| MEM %R              | 2.2     | 5.2           | 0          | 20        | 9.1        | 14           | 0          | 25          | 48.1                 | 19.4         |
| **Folate pathway antagonists** |          |               |            |           |            |              |            |             |                      |              |
| SXT %R              | 76.7    | 82.7          | 66.7       | 100       | 81.8       | 88           | 66.7       | 100         | 68.4                 | NA*          |
| **Quinolones and Fluoroquinolones** |          |               |            |           |            |              |            |             |                      |              |
| NA %R               | 83.3    | 80            | NA*        | NA*       | 0          | 100          | 0          | 100         | NA*                  | NA*          |
| CIP %R              | 62.9    | 62.3          | 25         | 87.5      | 66.7       | 71           | 50         | 60          | 77.6                 | 21.9         |
| **Tetracycline**    |          |               |            |           |            |              |            |             |                      |              |
| TET %R              | 84.8    | 60            | 66.7       | 60        | 50         | NA*          | NA*        | 0           | 92.9                 | 0            |
| **Nitrofurantoin**  |          |               |            |           |            |              |            |             |                      |              |
| FM %R               | 3.1     | 46.4          | 33.3       | 75        | 0          | NA*          | NA*        | NA*         | NA*                  | NA*          |
| **Aminoglycosides** |          |               |            |           |            |              |            |             |                      |              |
| GEN %R              | 20.5    | 71.2          | 0          | 66.7      | 60         | 25           | 0          | 33          | 72.7                 | 0            |
| TOB %R              | 33.6    | 37.2          | 25         | 72.7      | 57.1       | 63           | 0          | 25          | 54.3                 | 17.2         |
| AMK %R              | 3.1     | 11.1          | 0          | 12.5      | 0          | 46           | 0          | 0           | 29.5                 | 4.3          |

Abbreviations: AMP-Ampicillin, AMC-Amoxicillin-clavulanate, TZP-Piperacillin-tazobactam, CZ-Cefazolin, CXM-Cefuroxime, CRO-Ceftriaxone, CTX-Cefotaxime, CAZ-Ceftazidime, FEP-Cefepime, IPM-Imipenem, MEM-Meropenem, SXT-Trimethoprim-sulfamethoxazole, NA- Nalidixic acid, CIP-Ciprofloxacin, TET-Tetracycline, FM-Nitrofurantoin, GEN-Gentamycin, TOB-Tobramycin, AMK-Amikacin, %R-Percent resistant, NA* - Not Applicable, 0-Zero resistance.
Phenotypic antimicrobial resistance patterns of *P. aeruginosa*
A total of 36 *P. aeruginosa* isolates were obtained during the study period. The highest percentage of resistance by *P. aeruginosa* was observed against ciprofloxacin [N = 32, 21.9%], cefepime [N = 32, 21.7%], and meropenem [N = 31, 19.4%] (Table 5).

Discussion
The prevalence of XDR, MDR, carbapenemase-producing, and carbapenem-resistant GNB is increasing [5, 6, 37]. In our study, the prevalence of MDR, XDR, carbapenemase-producing, and carbapenem non-susceptible GNB is high.

Extensively drug resistant gram-negative bacilli
The most frequently isolated XDR organism was *Acinetobacter* species 32.4% [24/74] which disagree with the study findings of Beyene et al (*E. coli* 18.1% was the dominant XDR GNB followed by *K. pneumoniae* 11.1% [37] and Gashaw et al (*Klebsiella* species 43.3% was the dominant XDR GNB) [38]. The difference could be attributed to geographical differences, the number of samples studied, or the types of gram-negative bacteria considered. In the present study, the highest number of XDR organisms were recovered from urine samples 48.48% [16/33] and patients admitted to an intensive care unit 63.64% [21/33].

In the present study, the prevalence of XDR gram-negative bacilli was 7.7% [33/429], which is slightly lower than a study at Ethiopian Public Health Institute, Ethiopia by Beyene et al 8.8% [37]. This variation might be due to the investigators analyzing only Enterobacteriales and is much lower than the findings from the study at Jimma, Ethiopia by Gashaw et al 41.3% [38], Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia by Bitew et al 34.3% [39], and the Tertiary Care Hospital, Pakistan by Abbas et al 64% [40]. The variation might be due to geographic location, the technique utilized, XDR definition, types of organism, etc.

Carbapenemase producing gram negative bacilli
In our study, the prevalence of carbapenemase-producing gram-negative bacilli was 5.4%, which is higher than the prevalence of study conducted at the University of Gondar, Ethiopia by Eshetie et al at 2.72% [41] and the Ethiopian Public health Institute by Beyene et al at 2% [37]. However, our result was lower than the result of studies conducted at Tikur Anbessa Specialized Hospital, Ethiopia by Melese et al with 12.12% [42], Three Hospitals in Amhara region, Ethiopia by Moges et al 15.7% [43], Felegehiwot Hospital, Ethiopia by Moges et al 16.2% [44], Sidama, Ethiopia by Alemayehu et al 9% [45], Mulago National Referral Hospital, Uganda by Okoche et al 22.4% [46], and data from laboratories in Spain by Lopez-Hernandez et al 62% [47]. The variation might be due to the method utilized, i.e. the modified carbapenem inactivation method was utilized in our investigation unlike other investigators who used the modified Hodge test, the number of bacterial isolates analyzed, geographic location. However, our study findings are in line with a prospective cross-sectional study conducted at Felegehiwot Hospital, Ethiopia by Alebel et al 5.2% [48]. The dominant carbapenemase-producing gram-negative bacilli were *Klebsiella pneumoniae* 8.3% [9/109] followed by *Acinetobacter* species 6.8% [5/74]. Our study results marginally coincides with the findings of the following researchers which demonstrated the dominant prevalence of carbapenemase-producing *Klebsiella pneumoniae*: Beyene et al *Klebsiella pneumoniae* 5.6% [37], Melese et al *Klebsiella pneumoniae* 10.5% [42], Moges et al *Klebsiella pneumoniae* 5.8% [43], Moges et al *Klebsiella pneumoniae* 10.1% [44], Lopez-Hernandez *Klebsiella pneumoniae* 45% [47]. The present study disagrees with the findings by Okoche et al, which showed *E. coli* as the highest
carbapenemase-producing organisms [46]. The discrepancy could be explained by the fact that they utilized boronic acid-based inhibition, a modified Hodge test and EDTA double combination disk test, the number of samples analyzed, and a different geographical location.

The highest number of carbapenemase producing isolates were recovered from urine samples 13/23 (56.5%), which strongly disagrees with the results of study conducted by Moges et al in which the highest number of carbapenemase producing isolates was recovered from blood samples 22/24 (91.6%) [43].

**Multidrug resistant gram-negative bacilli**

The prevalence of MDR was 45.2% which is much lower than the study conducted at the Ethiopian Public Health Institute by Beyene et al 94.5% [37], three referral hospitals, Ethiopia by Moges et al 85.8% [43], Felegehiwot Hospital, Ethiopia by Moges et al 80% and by Alebel et al 81.1% [44, 48], Addis Ababa, Ethiopia by Teklu et al 68.3% [49], northern Iran by Hemmati 62.8% [50], and Jimma Medical Center, Ethiopia by Biset et al 56.67% [51]. The variation might be due to the study population, the number of isolates assessed or the test method utilized. However, our study findings are in line with the study conducted at Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia by Bitew et al 42.1% [39]. The dominant MDR isolates were *K. pneumoniae* 80 (73.4%); however our results disagree with the study findings of Beyene et al in which *E. coli* (99.3%) is the dominant one followed by *K. pneumoniae* (90.3%) [37]. The observed variation could be attributable to the study period and proportion of bacterial isolates, Alebel et al in which *Acinetobacter species* (100%), *P. aeruginosa* (100%), *Citrobacter* species (100%), and *Enterobacter cloacae* (100%) were the dominant MDR isolates [48]. This variation could be attributable to fewer samples evaluated, samples were taken from intensive care unit patients, or that the study was conducted in a different geographic location and Biset et al [51] the difference might be since they only analyzed urine samples among pregnant women. Likewise, the following researchers reported the dominant prevalence of MDR *Klebsiella* species Moges et al *Klebsiella* species (30.6%) [43], Moges et al. *K. pneumoniae* (53.3%) [44], and Teklu et al *K. pneumoniae* (83.5%) [49].

**Carbapenem-resistant gram-negative bacilli**

The prevalence of carbapenem-resistant gram-negative bacilli was 10.7% (46/429), in which *Acinetobacter* species account for about 39% of carbapenem-resistant isolates. This finding contradicts the study findings of the following researchers: Beyene et al 1.7% [37], Alebel et al 21% [48], Teklu et al 5.2% [49], Gashaw et al 25% [38], Melese et al 12.2% [42], in *K. pneumoniae* accounts for 100%, 40%, 50%, 36%, and 75% of the gram-negative bacilli isolates respectively. The observed difference could be attributed to different gram-negative bacteria analyzed, as most of them only included *Enterobacterales*, the techniques used, geographical location, and so on.

**Resistance patterns of Gram-negative bacilli to extended spectrum cephalosporins**

The total resistance profile of Enterobacterales to extended-spectrum cephalosporins ranges from 57.7% to 80.8%, which marginally agrees with results of study conducted by Beyene et al 73.5% to 73.9% [37], and by Breurec S et al 79.7% [52] but higher than the study findings of Teklu et al (60.3% to 62.2%) [49], Gashe F et al (56.5% to 60.1%) [53] and Moges et al (60.3% to 66%, in 2021) [43] lower than the study finding by Moges et al (87.2% to 96.6%, in 2019) [44]. The geographical location, study time, and quantity of samples analyzed could all be factors in the reported discrepancy. Extended spectrum cephalosporin resistance was found in
17.5% of clinical Enterobacterales isolates studied in North America and Europe between 2016 and 2018 [54]; the observed discrepancy could be attributed to the study’s large geographical scope, infection control techniques used in those settings, the number of samples tested, and other factors.

**Conclusion and recommendations**

This study revealed an alarming level of AMR, with a high prevalence of multidrug-resistant, extremely drug-resistant, carbapenemase-producing gram-negative bacteria, particularly among intensive care unit patients at the health facility level. These findings point to a scenario in which the clinical management of infected patients becomes increasingly difficult and necessitates the use of last-resort antimicrobials, likely exacerbating the magnitude of the global AMR crisis. This necessitates a robust antimicrobial resistance monitoring and infection prevention and control program at these institutions.

**Limitations of the study**

The responsible genes for carbapenemase production were not genotypically assessed. Further, patient clinical impact was not assessed. Tigecycline, colistin, and fosfomycin were not available and accordingly not used for AST.

**Supporting information**

S1 Data. Patient’s demographic and MDR data.
(XLSX)

S2 Data. Patient’s demographic, carbapenemase and extremely drug resistance data.
(XLSX)

**Acknowledgments**

My deepest appreciation would go to Ethiopian Public Health institute for their support of reagents and supplies to conduct this research, and Dr. Adane Bitew, Dr. Martin Evans and Dr. Eyasu Tigabu for their commitment in reviewing this manuscript.

**Author Contributions**

**Conceptualization:** Abera Abdeta.

**Data curation:** Abera Abdeta, Dawit Assefa, Tadesse Lejisa, Yordanos Kefyalew, Eyasu Tigabu.

**Formal analysis:** Abera Abdeta, Estifanos Tsige, Dawit Assefa, Tadesse Lejisa, Yordanos Kefyalew, Eyasu Tigabu.

**Funding acquisition:** Abera Abdeta.

**Investigation:** Abera Abdeta, Eyasu Tigabu.

**Methodology:** Abera Abdeta.

**Project administration:** Abera Abdeta.

**Software:** Abera Abdeta.

**Supervision:** Abera Abdeta, Adane Bitew, Surafel Fentaw, Estifanos Tsige, Eyasu Tigabu.

**Validation:** Abera Abdeta.
Visualization: Abera Abdeta, Adane Bitew, Surafel Fentaw, Estifanos Tsige, Eysasu Tigabu.

Writing – original draft: Abera Abdeta.

Writing – review & editing: Abera Abdeta, Adane Bitew, Surafel Fentaw, Estifanos Tsige, Dawit Assefa, Tadesse Lejisa, Yordanos Kefalyew, Eysasu Tigabu, Martin Evans.

References

1. Ventola CL. The Antimicrobial resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015 Apr; 40(4):277. PMID: 25859123

2. Aminov RI. A brief history of the antimicrobial era: lessons learned and challenges for the future. Frontiers in microbiology. 2010 Dec 8; 1:134. https://doi.org/10.3389/fmicb.2010.00134 PMID: 21687759

3. Rolain JM, Canton R, Cornaglia G. Emergence of Antimicrobial resistance: the need for a new paradigm. Clinical Microbiology and Infection. 2012 Jul 1; 18(7):615–6. https://doi.org/10.1111/j.1469-0691.2012.03902.x PMID: 22703444

4. Watkins RR, Bonomo RA. Overview: global and local impact of antimicrobial resistance. Infectious Disease Clinics. 2016 Jun 1; 30(2):313–22. https://doi.org/10.1016/j.idc.2016.02.001 PMID: 27208761

5. Souza GL, Rocha RF, Carvalho HD, Oliveira CD, Leite EM, Silva EU, et al. 2475. Incidence of Multi-drug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Gram-Negative Bacteria in Brazilian Intensive Care Units. In: Open Forum Infectious Diseases 2019 Oct 2 (Vol. 6).

6. Kieffer N, Nordmann P, Aires-de-Sousa M, Poirel L. High prevalence of carbapenemase-producing Enterobacteriaceae among hospitalized children in Luanda, Angola. Antimicrobial agents and chemotherapy. 2016 Oct 1; 60(10):6189–92. https://doi.org/10.1128/AAC.01201-16 PMID: 27503638

7. Zhou L, Feng S, Sun G, Tang B, Zhu X, Song K, et al. Extensively drug-resistant Gram-negative bacterial bloodstream infection in hematological disease. Infection and drug resistance. 2018; 12:481. https://doi.org/10.2147/IDR.S191462 PMID: 30881053

8. World Health Organization. Antimicrobial resistance global report on surveillance: 2014 summary. World Health Organization; 2014.

9. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Turnietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clinical infectious diseases. 2012 Oct 1; 55(7):943–50. https://doi.org/10.1093/cid/cis588 PMID: 22752516

10. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerging infectious diseases. 2011 Oct; 17(10):1791. https://doi.org/10.3201/eid1710.110655 PMID: 22003047

11. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.

12. Aliramezani A, Soleimani M, Fard RM, Nojoomi F. Virulence determinants and biofilm formation of Acinetobacter baumannii isolated from hospitalized patients. Germs. 2019 Sep; 9(3):148. https://doi.org/10.18683/germs.2019.9.3.148 PMID: 31646145

13. Alonso B, Fernández-Barat L, Di Domenico EG, Marín M, Cercenado E, Merino I, et al. Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia. BMC infectious diseases. 2020 Dec; 20(1):1–8.

14. Khaertynov KS, Anokhin VA, Rizvanov AA, Davidyuk YN, Semenova DR, Lubin SA, et al. Virulence factors and antibiotic resistance of Klebsiella pneumoniae strains isolated from neonates with sepsis. Frontiers in medicine. 2018 Aug 14; 5:225. https://doi.org/10.3389/fmed.2018.00225 PMID: 30155466

15. Mainil J. Escherichia coli virulence factors. Veterinary immunology and immunopathology. 2013 Mar 15; 152(1–2):2–12. https://doi.org/10.1016/j.vetimm.2012.09.032 PMID: 23083936

16. Siqueira JF Jr, Rôças IN. Bacterial pathogenesis and mediators in apical periodontitis. Brazilian dental journal. 2007; 18(4):267–80. https://doi.org/10.1590/s0103-64402007000400001 PMID: 18278296

17. Makharita RR, El-Kholy I, Hetta HF, Abdelaziz MH, Hagagy FI, Ahmed AA, et al. Antiobigram and genetic characterization of carbapenem-resistant gram-negative pathogens incriminated in healthcare-associated infections. Infection and drug resistance. 2020; 13:3991. https://doi.org/10.2147/IDR.S276975 PMID: 33177849

18. Abolghait SK, Fathi AG, Youssef FM, Algamal AM. Methicillin-resistant Staphylococcus aureus (MRSA) isolated from chicken meat and giblets often produces staphyloccocal enterotoxin B (SEB) in
Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli

non-refrigerated raw chicken livers. International Journal of Food Microbiology. 2020 Sep 2; 328:108669. https://doi.org/10.1016/j.ijfoodmicro.2020.108669 PMID: 32497922

19. Algammal AM, Hetta HF, Elkelish A, Alkhalfah DH, Hozzein WN, Batigha GE, et al. Methicillin-Resistant Staphylococcus aureus (MRSA): one health perspective approach to the bacteriology epidemiology, virulence factors, antibiotic-resistance, and zoonotic impact. Infection and Drug Resistance. 2020; 13:3255. https://doi.org/10.2147/IDR.S272733 PMID: 33061472

20. Algammal AM, Hashem HR, Alfifi KJ, Hetta HF, Sheraba NS, Ramadan H, et al. atp D gene sequencing, multdrug resistance traits, virulence-determinants, and antimicrobial resistance genes of emerging XDR and MDR Proteus mirabilis. Scientific reports. 2021 May 4; 11(1):1–5. https://doi.org/10.1038/s41598-020-79139-8 PMID: 33414495

21. Algammal AM, El-Sayed ME, Youssef FM, Saad SA, Elhaig MM, Batiha GE, et al. Prevalence, the antibiotic-resistance, and zoonotic impact. Infection and Drug Resistance. 2020; 13:2056. https://doi.org/10.1186/s13756-020-01037-z PMID: 32472209

22. Algammal AM, Mabrok M, Sivaramasamy E, Youssef FM, Atwa MH, El-Kholy AW, et al. Emerging MDR-Pseudomonas aeruginosa in fish commonly harbor opr L and tox A virulence genes and bla TEM, bla CTX-M, and tet A antibiotic-resistance genes. Scientific Reports. 2020 Sep 29; 10(1):1–8. https://doi.org/10.1038/s41598-019-56847-4 PMID: 31913322

23. Algammal AM, Hetta HF, Batigha GE, Hozzein WN, El Kazzaz WM, Hashem HR, et al. Virulence-determinants and antibiotic-resistance genes of MDR-E. coli isolated from secondary infections following FMD-outbreak in cattle. Scientific Reports. 2020 Nov 13; 10(1):1–3. https://doi.org/10.1038/s41598-019-56847-4 PMID: 31913322

24. Algammal AM, Mohamed MF, Tawfiek BA, Hozzein WN, El Kazzaz WM, Mabrok M, Molecular typing, antibiogram and PCR-RFLP based detection of Aeromonas hydrophila complex isolated from Oreochromis niloticus. Pathogens. 2020 Mar; 9(3):238. https://doi.org/10.3390/pathogens9030238 PMID: 32235800

25. Magiorakos AP, Srinivasan A, Carey RT, Carmeli Y, Falagas MT, Giske CT, et al. Multidrug-resistant, extensively drug-resistant and pan-drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection. 2012 Mar 1; 18(3):268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x PMID: 21793988

26. Walther-Rasmussen J, Heiby N. OXA-type carbapenemases. Journal of Antimicrobial Chemotherapy. 2006 Mar 1; 57(3):373–83. https://doi.org/10.1093/jac/dki482 PMID: 16446375

27. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrobial agents and chemotherapy. 2010 Feb 1; 54(2):890–7. https://doi.org/10.1128/AAC.00693-09 PMID: 20008772

28. Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2018 Dec; 7(1):1–4. https://doi.org/10.1186/s13756-018-0370-9 PMID: 29997889

29. Leber AL. Clinical Microbiology procedures handbook (Fourth edition).

30. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

31. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 22th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.

32. van der Zwaluw K, de Haan A, Pluister GN, Bootsma HJ, de Neeling AJ, Schouls LM. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PloS one. 2015 Mar 23; 10(3):e0123690. https://doi.org/10.1371/journal.pone.0123690 PMID: 25798828

33. Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae. Journal of clinical microbiology. 2017 Aug 1; 55(8):2321–33. https://doi.org/10.1128/JCM.00193-17 PMID: 28381609

34. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

35. Jing X, Zhou H, Min X, Zhang X, Yang Q, Du S, et al. The simplified carbapenem inactivation method (sCIM) for simple and accurate detection of carbapenemase-producing Gram-negative bacilli. Frontiers in microbiology. 2018 Oct 30; 9:2391. https://doi.org/10.3389/fmicb.2018.02391 PMID: 30425686

36. Use I, Of C, Packages THE, Samples K, Procedure T, Results ETHE. MIC Test Strip Technical Sheet KPC: 2015;7–8.
37. Beyene D, Bitew A, Fantew S, Mihret A, Evans M. Multidrug-resistant profile and prevalence of extended-spectrum β-lactamase and carbapenemase production in fermentative Gram-negative bacilli recovered from patients and specimens referred to National Reference Laboratory, Addis Ababa, Ethiopia. PLoS one. 2019 Sep 25; 14(9):e0222911. https://doi.org/10.1371/journal.pone.0222911 PMID: 31553773

38. Gashaw M, Berhane M, Bekele S, Kibru G, Teshaeger L, Yilma Y, et al. Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrobial Resistance & Infection Control. 2018 Dec; 7(1):1–8. https://doi.org/10.1186/s13756-018-0431-0 PMID: 30479751

39. Bitew A, Tsige E. High Prevalence of Multidrug-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Cross-Sectional Study at Arsha HospitaL Medical Laboratory, Addis Ababa, Ethiopia. Journal of tropical medicine. 2020 Apr 30;2020.

40. Abbas S, Sabir AU, Khalid N, Sabir S, Khalid S, Haseeb S, et al. Frequency of Extensively Drug-Resistant Gram-Negative Pathogens in a Tertiary Care Hospital in Pakistan. Cureus. 2020 Dec; 12(12).

41. Eshtie S, Unakal C, Gelaw A, Ayelign B, Endris M, Moges F. Multidrug resistant and carbapenemase producing Enterobacteriaceae among patients with urinary tract infection at referral Hospital, Northwest Ethiopia. Antimicrobial resistance and infection control. 2015 Dec; 4(1):1–8. https://doi.org/10.1186/s13756-015-0054-7 PMID: 25908966

42. Legese MH, Weldearegay GM, Asrat D. Extended-spectrum beta-lactamase-and carbapenemase-producing Enterobacteriaceae among Ethiopian children. Infection and drug resistance. 2017: 10:27. https://doi.org/10.2147/IDR.S281214

43. Moges F, Gizachew M, Dagnew M, Amare A, Sharew B, Eshtie S, et al. Multidrug resistance and extended-spectrum beta-lactamase producing Gram-negative bacteria from three Referral Hospitals of Amhara region, Ethiopia. Annals of clinical microbiology and antimicrobials. 2021 Dec; 20(1):1–2. https://doi.org/10.1186/s12941-020-00409-4 PMID: 33402178

44. Moges F, Eshtie S, Abebe W, Mekonnen F, Dagnew M, Endale A, et al. High prevalence of extended-spectrum beta-lactamase-producing gram-negative pathogens from patients attending Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Amhara region. PLoS one. 2019 Apr 15; 14(4): e0215177. https://doi.org/10.1371/journal.pone.0215177 PMID: 30986262

45. Alemayehu T, Asnake S, Tadesse B, Azerefegn E, Mitiku E, Agegnehu A, et al. Phenotypic Detection of Carbapenem-Resistant Gram-Negative Bacilli from a Clinical Specimen in Sidama, Ethiopia: A Cross-Sectional Study. Infection and Drug Resistance. 2021; 14:369. https://doi.org/10.2147/IDR.S289763 PMID: 33564245

46. Okoche D, Asimwe BB, Katabazi FA, Kato L, Najjuka CF. Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS One. 2015 Aug 18; 10(8):e0135745. https://doi.org/10.1371/journal.pone.0135745 PMID: 26284519

47. López-Hernández I, Delgado-Valverde M, Fernández-Cuenca F, López-Cerero L, Machuca J, Pascual Á. Carbapenem-Producing gram-negative bacteria from Andalucia, Spain, 2014–2018. Emerging Infectious Diseases. 2020 Sep; 26(9):2218. https://doi.org/10.3201/eid2609.191772 PMID: 32818413

48. Abebe M, Mekonnen F, Mulu W. Extended-spectrum β-Lactamase and Carbapenemase Producing Gram-Negative Bacilli Infections Among Patients in Intensive Care Units of Felegehiwot Referral Hospital: A Prospective Cross-Sectional Study. Infection and Drug Resistance. 2021; 14:391. https://doi.org/10.2147/IDR.S292246

49. Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD. Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia. Antimicrobial Resistance & Infection Control. 2019 Dec; 8(1):1–7. https://doi.org/10.1186/s13756-019-0488-4 PMID: 30815254

50. Hemmati H, Hasannejad-Bibalan M, Khoshhoz S, Khoshhoz P, Kalurazi TY, Ebrahim-Saraie HS, et al. Two years study of prevalence and antibiotic resistance pattern of Gram-negative bacteria isolated from surgical site infections in the North of Iran. BMC research notes. 2020 Dec; 13(1):1–6. https://doi.org/10.1186/s13104-019-1977-7 PMID: 3159526

51. Biset S, Moges F, Endalamaw D, Eshtie S. Multi-drug resistant and extended-spectrum β-lactamases producing bacterial uropathogens among pregnant women in Northwest Ethiopia. Annals of Clinical Microbiology and Antimicrobials. 2020 Dec; 19:1–9. https://doi.org/10.1186/s12941-019-0343-8 PMID: 31918737

52. Breurec S, Bouchiat C, Sire JM, Moquet O, Bercion R, Cisse MF, et al. High third-generation cephalosporin resistant Enterobacteriaceae prevalence rate among neonatal infections in Dakar, Senegal. BMC infectious diseases. 2016 Dec; 16(1):1–7. https://doi.org/10.1186/s12879-016-1935-y PMID: 27785017
53. Gashe F, Mulisa E, Mekonnen M, Zeleke G. Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins. Journal of pharmaceutics. 2018 Sep 9; 2018:5070742-. https://doi.org/10.1155/2018/5070742 PMID: 30271652

54. Belley A, Morrissey I, Hawser S, Kothari N, Knechtle P. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam. Journal of global antimicrobial resistance. 2021 Jun 1; 25:93–101. https://doi.org/10.1016/j.jgar.2021.02.031 PMID: 33746112